Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Benitec Biopharma Inc.NASDAQ: BNTC
Accumulated OCI · Q3 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q3 FY2026 Accumulated OCI was -$952K, compared with -$716K a year earlier.
Context
- Accumulated OCI amounted to 0.5% of total assets at the end of Q3 FY2026, down 0.2 pp from a year earlier.
- Accumulated OCI grew in size in 1 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -33.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (839K) USD
- Year-over-year change
- +5.9%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (839K) | +5.9% |
| FY2024 | 2024-06-30 | (892K) | -7.5% |
| FY2023 | 2023-06-30 | (830K) | +33.3% |
| FY2022 | 2022-06-30 | (1.25M) | +14.4% |
| FY2021 | 2021-06-30 | (1.46M) | — |
Accumulated OCI vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 Accumulated OCI of -$952K is the 8th highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -33.0% is the 4th highest of 8, against a peer median of -99.9%.
- Accumulated OCI amounts to 0.5% of total assets for BNTC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $182K | -99.9% | — | 0.0% | |
| Mar 2026 | $164K | +310.0% | +32.9% | 0.3% | |
| Mar 2026 | $119K | +0.8% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$13K | -750.0% | — | 0.0% | |
| Mar 2026 | -$382K | -19000.0% | — | 0.2% | |
| Mar 2026 | -$952K | -33.0% | — | 0.5% | |
| Mar 2026 | -$6.63M | +63.4% | — | 1.3% | |
| Mar 2026 | -$7.94M | -196.2% | — | 7.3% | |
| Peer median (excluding BNTC) | $0 | -99.9% | +32.9% | 0.0% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.